Skip to main content
Caplight Logo









BioVinc

BioVinc

Private
Pasadena, CaliforniaHealthcare & Life Scienceshttps://biovinc.com/

Last Round

Grant

Mar 3, 2023

Total Funding Raised

$7.2M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

BioVinc is a biotechnology company that develops bone-targeted therapeutics and diagnostic molecular probes for the treatment of bone diseases and infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Data as a Service

AI Layer

Non-AI

Keywords

drug deliverybone-targetingbisphosphonatedrug conjugatestargeted therapybiotechnologymolecular probesbone oncologymetabolic bone diseasesmall business innovation researchSBIRdrug discoverysmart drugsprecision medicinebiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioVinc Comparables

Compare BioVinc with similar companies based on industry and business-model similarity.

BioVinc comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MBC Pharma, Inc.
92%
Atlanthera
90%
Mesentech Inc.
85%

BioVinc Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 3, 2023
GrantAug 21, 2015

Key People

Founding team and executive leadership

Shuting Sun

Chief Executive Officer

Executive Team

BioVinc Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 184% MoM, reaching 1.4K.

  • Apr 6, 2026

    Monthly visitors increased 59% MoM.

BioVinc Filings

Explore SEC and related filing metadata, where available.

BioVinc filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BioVinc's valuation, stock price, and market status.

Is BioVinc a public or private company?

BioVinc is a private company.

What is the current stock price of BioVinc?

BioVinc is a private company with no public stock price. No recent secondary market data is available.

How much is BioVinc worth (valuation)?

Valuation information for BioVinc is not publicly available.

Can I buy BioVinc stock?

BioVinc shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BioVinc's last funding round?

BioVinc's most recent funding round was Grant on March 3, 2023.

Who are the main investors in BioVinc?

Key investors in BioVinc include National Institute of Allergy and Infectious Diseases, NIH RADx, National Institute of Dental and Craniofacial Research.

Will BioVinc IPO soon?

No public IPO plans have been announced for BioVinc.

How can I track BioVinc secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BioVinc's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPasadena, California
Employee Range3
Year Founded2014
Last FundingMar 3, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?